Navamedic Valuation

Is NAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NAVA (NOK31.6) is trading below our estimate of fair value (NOK165.59)

Significantly Below Fair Value: NAVA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAVA?

Other financial metrics that can be useful for relative valuation.

NAVA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA10.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does NAVA's PE Ratio compare to its peers?

The above table shows the PE ratio for NAVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.9x
VISTN Vistin Pharma
18.2xn/aNOK 1.2b
PHO Photocure
108.9x88.7%NOK 1.4b
AZT ArcticZymes Technologies
58.9x54.1%NOK 861.1m
539730 Fredun Pharmaceuticals
21.7xn/a₹3.8b
NAVA Navamedic
22.7x27.0%NOK 558.1m

Price-To-Earnings vs Peers: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (51.8x).


Price to Earnings Ratio vs Industry

How does NAVA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the European Pharmaceuticals industry average (22.7x).


Price to Earnings Ratio vs Fair Ratio

What is NAVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: NAVA is good value based on its Price-To-Earnings Ratio (22.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 31.40
NOK 45.50
+44.9%
1.1%NOK 46.00NOK 45.00n/a2
Sep ’25NOK 29.10
NOK 45.50
+56.4%
1.1%NOK 46.00NOK 45.00n/a2
Aug ’25NOK 32.00
NOK 46.50
+45.3%
1.1%NOK 47.00NOK 46.00n/a2
Jul ’25NOK 33.00
NOK 46.50
+40.9%
1.1%NOK 47.00NOK 46.00n/a2
Jun ’25NOK 33.90
NOK 49.00
+44.5%
6.1%NOK 52.00NOK 46.00n/a2
May ’25NOK 32.40
NOK 49.00
+51.2%
6.1%NOK 52.00NOK 46.00n/a2
Apr ’25NOK 35.60
NOK 51.00
+43.3%
2.0%NOK 52.00NOK 50.00n/a2
Mar ’25NOK 37.00
NOK 49.00
+32.4%
2.0%NOK 50.00NOK 48.00n/a2
Feb ’25NOK 38.50
NOK 49.00
+27.3%
2.0%NOK 50.00NOK 48.00n/a2
Jan ’25NOK 36.70
NOK 49.00
+33.5%
2.0%NOK 50.00NOK 48.00n/a2
Dec ’24NOK 38.50
NOK 49.00
+27.3%
2.0%NOK 50.00NOK 48.00n/a2
Nov ’24NOK 38.90
NOK 47.00
+20.8%
6.4%NOK 50.00NOK 44.00n/a2
Oct ’24NOK 39.30
NOK 47.00
+19.6%
6.4%NOK 50.00NOK 44.00NOK 30.102
Sep ’24NOK 32.00
NOK 47.00
+46.9%
6.4%NOK 50.00NOK 44.00NOK 29.102
Aug ’24NOK 36.80
NOK 50.50
+37.2%
5.0%NOK 53.00NOK 48.00NOK 32.002
Jul ’24NOK 38.50
NOK 49.00
+27.3%
8.2%NOK 53.00NOK 45.00NOK 33.002
Jun ’24NOK 37.90
NOK 49.00
+29.3%
8.2%NOK 53.00NOK 45.00NOK 33.902
May ’24NOK 36.40
NOK 50.00
+37.4%
10.0%NOK 55.00NOK 45.00NOK 32.402
Apr ’24NOK 40.10
NOK 50.00
+24.7%
10.0%NOK 55.00NOK 45.00NOK 35.602
Mar ’24NOK 36.50
NOK 50.00
+37.0%
10.0%NOK 55.00NOK 45.00NOK 37.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies